STOCK TITAN

Xcelerate, Inc. Unveils Website That Crosses the Divide Between Non-Medical Engineering and Clinical Care

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Xcelerate, Inc. (OTC: XCRT) has launched a new website, www.xcelerate.global, highlighting its innovative role in integrating advanced engineering solutions with MedTech and clinical care. The website aims to communicate the company's mission, progress, and potential within the MedTech sector, serving as a platform for updates and news. CEO Michael O'Shea emphasized that the global domain reflects the company’s aspirations for international growth and collaboration. Xcelerate focuses on acquiring patents and engineering technologies and is committed to advancing early-stage medical technologies.

Positive
  • Launch of a new website to enhance communication about the company's mission and growth.
  • The website serves as a platform for updates, increasing visibility in the MedTech sector.
  • Emphasis on integrating advanced engineering with clinical care could attract partnerships and investments.
Negative
  • None.

MAULDIN, S.C., April 29, 2021 /PRNewswire/ -- Xcelerate, Inc. (OTC: "XCRT"), unveiled an innovative website www.xcelerate.global encompassing its emergence as a leader in bringing together advanced engineering solutions, MedTech producers and clinical care settings into a unified, productive system.

The new Xcelerate website will communicate the company's mission, growth, success, and the full potential of MedTech development and healthcare delivery.  The site will serve as a platform for publishing Xcelerate's latest developments and news while sharing its Twitter feed @XcelerateUS. The website also will explain more about the inner workings of Xcelerate and its expanding board of distinguished advisors, as well as the growing company's directors, science officer and counsel.

"The unveiling of the official website for Xcelerate, Inc. is a huge step toward achieving our mission of bridging the gap between advanced engineering and medicine," said Chief Executive Officer and Director of Xcelerate, Inc. Michael O'Shea. "We chose dot global, not dot com because Xcelerate is a global company, and we look forward to keep growing," O'Shea added.

For more information on Xcelerate, Inc, please visit www.xcelerate.global. and follow them on Twitter @XcelerateUS.  Media contact: Justin Baronoff 561-750-9800; justin@transmediagroup.com.

ABOUT XCELERATE
Xcelerate is a company seeking innovative acquisitions within the patent/engineering world and focused on joining early-stage medical technology companies in a setting that is a controlled clinical care where these new developments can be trailed, tested, and applied.

Media Contact: Justin Baronoff, justin@transmediagroup.com  (561) 750-9800

Cision View original content:http://www.prnewswire.com/news-releases/xcelerate-inc-unveils-website-that-crosses-the-divide-between-non-medical-engineering-and-clinical-care-301280109.html

SOURCE Xcelerate, Inc.

FAQ

What is the significance of Xcelerate's new website launch?

The website aims to enhance communication about Xcelerate's mission and MedTech developments, positioning the company as a leader in the integration of engineering and healthcare.

What is the focus of Xcelerate, Inc.?

Xcelerate focuses on acquiring innovative patents and engineering technologies to support early-stage medical technology development.

How does Xcelerate plan to communicate its updates?

Through its new website, Xcelerate will publish developments and news, increasing its visibility in the industry.

What does CEO Michael O'Shea say about the website?

He stated that the launch is a significant step towards bridging the gap between advanced engineering and medicine, highlighting growth opportunities.

When was the Xcelerate website launched?

The website was unveiled on April 29, 2021.

XCELERATE INC

OTC:XCRT

XCRT Rankings

XCRT Latest News

XCRT Stock Data

10.73M
254.49M
41.61%
Medical Care Facilities
Healthcare
Link
United States of America
Mauldin